Ambu A/S (CPH: AMBU.B)
Denmark
· Delayed Price · Currency is DKK | Market Cap | 34.08B |
| Revenue (ttm) | 5.26B |
| Net Income (ttm) | 450.00M |
| Shares Out | 266.39M |
| EPS (ttm) | 1.69 |
| PE Ratio | 75.88 |
| Forward PE | 55.97 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,853,295 |
| Open | 145.70 |
| Previous Close | 153.05 |
| Day's Range | 126.45 - 146.40 |
| 52-Week Range | 65.62 - 154.60 |
| Beta | 0.74 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 30, 2024 |
About Ambu A/S
Ambu A/S develops, produces, and sells medical devices to hospitals, clinics, and rescue services worldwide. The company offers anaesthesia, and patient monitoring and diagnostics products. The company also offers endoscopy products, such as bronchoscopes, rhinolaryngoscopes, duodenoscopes, cystoscopes, and display units; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of airway management and anaesthesia products, such as br... [Read more]
Financial Performance
In 2023, Ambu A/S's revenue was 4.78 billion, an increase of 7.45% compared to the previous year's 4.44 billion. Earnings were 168.00 million, an increase of 80.65%.
Financial StatementsNews
ANNUAL REPORT 2022/23 (EARNINGS RELEASE)
For the full 2022/23 financial year, Ambu reported 7.6% organic revenue growth. This was driven by Endoscope Solutions posting 15% organic growth, the main drivers being urology and ENT growing high d...
Ambu A/S: Reporting of transactions made by persons discharging managerial responsibilities
Pursuant to the Market Abuse Regulation, article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S...